Literature DB >> 11994155

Expression, mutagenesis and kinetic analysis of recombinant K1E endosialidase to define the site of proteolytic processing and requirements for catalysis.

Daniel R Leggate1, J Mark Bryant, Maria B Redpath, Denise Head, Peter W Taylor, J Paul Luzio.   

Abstract

Catalytically active, recombinant fusion proteins of bacteriophage E endosialidase were expressed and purified from Escherichia coli. Constructs with different fusion partners added to the amino terminus of the endosialidase were enzymatically active. A post-translational proteolytic cleavage was shown to occur between serine 706 and aspartate 707 to generate the 76 kDa mature enzyme from the 90 kDa translation product. Endosialidase truncated at the C-terminus from aspartate 707 was observed to have the same 76 kDa molecular weight as wild-type enzyme using denaturing SDS-PAGE but, under native PAGE conditions, was not observed to form the approximately 250 kDa trimeric wild-type enzyme, implying that the C-terminus of the enzyme may be required for correct assembly of active trimer, rather than as part of the active site as has been previously suggested. Mutagenesis of aspartate 138 to alanine greatly reduced enzyme activity whereas conversion of other selected aspartate residues to alanine had less effect, consistent with similarities between the structure and cata-lytic mechanism of bacteriophage E endosialidase and those of exosialidases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994155      PMCID: PMC2034677          DOI: 10.1046/j.1365-2958.2002.02908.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  55 in total

1.  Sialidase-like Asp-boxes: sequence-similar structures within different protein folds.

Authors:  R R Copley; R B Russell; C P Ponting
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

2.  Structure and function of a novel coliphage-associated sialidase.

Authors:  Y Machida; K Miyake; K Hattori; S Yamamoto; M Kawase; S Iijima
Journal:  FEMS Microbiol Lett       Date:  2000-01-15       Impact factor: 2.742

3.  Evaluation and improvement of multiple sequence methods for protein secondary structure prediction.

Authors:  J A Cuff; G J Barton
Journal:  Proteins       Date:  1999-03-01

Review 4.  Prophylaxis and treatment of influenza virus infection.

Authors:  R Kandel; K L Hartshorn
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

Review 5.  A novel approach to antiviral therapy for influenza.

Authors:  P M Colman
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

Review 6.  Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions.

Authors:  U Rutishauser; L Landmesser
Journal:  Trends Neurosci       Date:  1996-10       Impact factor: 13.837

7.  Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli.

Authors:  D Scholl; S Rogers; S Adhya; C R Merril
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer.

Authors:  F Tanaka; Y Otake; T Nakagawa; Y Kawano; R Miyahara; M Li; K Yanagihara; J Nakayama; I Fujimoto; K Ikenaka; H Wada
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

9.  Engineering proteins that bind to cell surface carbohydrates.

Authors:  J P Luzio; J M Bryant; P W Taylor
Journal:  Clin Chim Acta       Date:  1997-10-09       Impact factor: 3.786

Review 10.  'Flu' and structure-based drug design.

Authors:  R C Wade
Journal:  Structure       Date:  1997-09-15       Impact factor: 5.006

View more
  10 in total

1.  Escherichia coli K1's capsule is a barrier to bacteriophage T7.

Authors:  Dean Scholl; Sankar Adhya; Carl Merril
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

2.  Genomic and Biochemical Characterization of Acinetobacter Podophage Petty Reveals a Novel Lysis Mechanism and Tail-Associated Depolymerase Activity.

Authors:  A C Hernandez-Morales; L L Lessor; T L Wood; D Migl; E M Mijalis; J Cahill; W K Russell; R F Young; J J Gill
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

3.  Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.

Authors:  Andrea Zelmer; Melissa J Martin; Ozan Gundogdu; George Birchenough; Rebecca Lever; Brendan W Wren; J Paul Luzio; Peter W Taylor
Journal:  Microbiology (Reading)       Date:  2010-04-15       Impact factor: 2.777

4.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

5.  Differential expression of the polysialyl capsule during blood-to-brain transit of neuropathogenic Escherichia coli K1.

Authors:  Andrea Zelmer; Mark Bowen; Anne Jokilammi; Jukka Finne; J Paul Luzio; Peter W Taylor
Journal:  Microbiology       Date:  2008-08       Impact factor: 2.777

6.  Identification of amino acid residues at the active site of endosialidase that dissociate the polysialic acid binding and cleaving activities in Escherichia coli K1 bacteriophages.

Authors:  Elina Jakobsson; Anne Jokilammi; Juha Aalto; Pauli Ollikka; Jukka V Lehtonen; Harri Hirvonen; Jukka Finne
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

7.  Therapeutic Application of Phage Capsule Depolymerases against K1, K5, and K30 Capsulated E. coli in Mice.

Authors:  Han Lin; Matthew L Paff; Ian J Molineux; James J Bull
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

8.  Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype.

Authors:  Naseem Mushtaq; Maria B Redpath; J Paul Luzio; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.

Authors:  Christopher D Scharer; Noelani Laycock; Adeboye O Osunkoya; Sanjay Logani; John F McDonald; Benedict B Benigno; Carlos S Moreno
Journal:  J Transl Med       Date:  2008-12-11       Impact factor: 5.531

10.  Characterisation of Bacteriophage-Encoded Depolymerases Selective for Key Klebsiella pneumoniae Capsular Exopolysaccharides.

Authors:  George Blundell-Hunter; Mark C Enright; David Negus; Matthew J Dorman; Gemma E Beecham; Derek J Pickard; Phitchayapak Wintachai; Supayang P Voravuthikunchai; Nicholas R Thomson; Peter W Taylor
Journal:  Front Cell Infect Microbiol       Date:  2021-06-18       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.